<?xml version="1.0" encoding="UTF-8"?>
<p id="p0185">Although there are many therapeutic mAbs for treating different types of diseases on the market, however few therapeutic mAbs are approved as antiviral agents. This can be due to various reasons, but some challenges can be solved with minimizing and engineering the antibodies. So far, there are no antiviral biopharmaceuticals based on antibody fragments, but many efforts being currently concentrated on these types of therapeutics for viral infections, and it is expected that in the near future these products will enter clinical phases and even enter the market and be a significant body of therapeutic agents against infectious diseases especially viral targets.</p>
